ReviewFrontiers in nutrition2026
Vitamin E in diabetes-associated cognitive dysfunction: mechanistic rationale, current evidence and translational gaps.
Review in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes-associated cognitive dysfunction (DACD) is an increasingly recognized complication of diabetes mellitus and involves multiple interacting processes, including oxidative stress, neuroinflammation, synaptic dysfunction, impaired insulin signaling, and neurovascular dysfunction. Vitamin E, a lipid-soluble antioxidant comprising tocopherols and tocotrienols, has attracted interest because several of its biological actions are mechanistically relevant to these pathways. This mini-review provides a focused overview of the mechanistic rationale, current experimental and clinical evidence, and major translational gaps concerning vitamin E in DACD. Preclinical studies suggest that specific vitamin E isoforms and preparations may modulate oxidative stress and lipid peroxidation, inflammatory signaling and microglial activation, synaptic plasticity-related pathways, and insulin responsiveness, and may also influence neurovascular processes. However, much of this evidence derives from animal models, cellular systems, peripheral tissues, or disease settings other than DACD and therefore provides mechanistic rather than clinical efficacy evidence. Direct clinical evidence in patients with formally diagnosed DACD remains lacking. Small intervention studies in patients with type 2 diabetes have reported inconsistent cognitive outcomes, whereas observational associations between dietary vitamin E intake and cognition are largely derived from non-DACD populations and cannot establish causality. High-dose supplementation may also entail safety concerns. Thus, current evidence supports the biological plausibility of vitamin E as a candidate for further investigation but does not establish its preventive or therapeutic efficacy in DACD. DACD-specific randomized controlled trials are needed to determine whether particular vitamin E isoforms, doses, or intervention durations provide clinically meaningful cognitive benefits and to establish long-term safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.